Literature DB >> 23999870

Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Andrea de Bartolomeis1, Gianmarco Latte, Carmine Tomasetti, Felice Iasevoli.   

Abstract

Emerging researches point to a relevant role of postsynaptic density (PSD) proteins, such as PSD-95, Homer, Shank, and DISC-1, in the pathophysiology of schizophrenia and autism spectrum disorders. The PSD is a thickness, detectable at electronic microscopy, localized at the postsynaptic membrane of glutamatergic synapses, and made by scaffolding proteins, receptors, and effector proteins; it is considered a structural and functional crossroad where multiple neurotransmitter systems converge, including the dopaminergic, serotonergic, and glutamatergic ones, which are all implicated in the pathophysiology of psychosis. Decreased PSD-95 protein levels have been reported in postmortem brains of schizophrenia patients. Variants of Homer1, a key PSD protein for glutamate signaling, have been associated with schizophrenia symptoms severity and therapeutic response. Mutations in Shank gene have been recognized in autism spectrum disorder patients, as well as reported to be associated to behaviors reminiscent of schizophrenia symptoms when expressed in genetically engineered mice. Here, we provide a critical appraisal of PSD proteins role in the pathophysiology of schizophrenia and autism spectrum disorders. Then, we discuss how antipsychotics may affect PSD proteins in brain regions relevant to psychosis pathophysiology, possibly by controlling synaptic plasticity and dendritic spine rearrangements through the modulation of glutamate-related targets. We finally provide a framework that may explain how PSD proteins might be useful candidates to develop new therapeutic approaches for schizophrenia and related disorders in which there is a need for new biological treatments, especially against some symptom domains, such as negative symptoms, that are poorly affected by current antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999870     DOI: 10.1007/s12035-013-8534-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  180 in total

1.  Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine.

Authors:  Daniela Polese; Antonella Amato de Serpis; Alberto Ambesi-Impiombato; Giovanni Muscettola; Andrea de Bartolomeis
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

Review 2.  Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins.

Authors:  Guillermo M Elias; Roger A Nicoll
Journal:  Trends Cell Biol       Date:  2007-07-20       Impact factor: 20.808

3.  PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.

Authors:  Atheir I Abbas; Prem N Yadav; Wei-Dong Yao; Margaret I Arbuckle; Seth G N Grant; Marc G Caron; Bryan L Roth
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

4.  SHANK1 Deletions in Males with Autism Spectrum Disorder.

Authors:  Daisuke Sato; Anath C Lionel; Claire S Leblond; Aparna Prasad; Dalila Pinto; Susan Walker; Irene O'Connor; Carolyn Russell; Irene E Drmic; Fadi F Hamdan; Jacques L Michaud; Volker Endris; Ralph Roeth; Richard Delorme; Guillaume Huguet; Marion Leboyer; Maria Rastam; Christopher Gillberg; Mark Lathrop; Dimitri J Stavropoulos; Evdokia Anagnostou; Rosanna Weksberg; Eric Fombonne; Lonnie Zwaigenbaum; Bridget A Fernandez; Wendy Roberts; Gudrun A Rappold; Christian R Marshall; Thomas Bourgeron; Peter Szatmari; Stephen W Scherer
Journal:  Am J Hum Genet       Date:  2012-04-12       Impact factor: 11.025

5.  The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function.

Authors:  Q Wang; E I Charych; V L Pulito; J B Lee; N M Graziane; R A Crozier; R Revilla-Sanchez; M P Kelly; A J Dunlop; H Murdoch; N Taylor; Y Xie; M Pausch; A Hayashi-Takagi; K Ishizuka; S Seshadri; B Bates; K Kariya; A Sawa; R J Weinberg; S J Moss; M D Houslay; Z Yan; N J Brandon
Journal:  Mol Psychiatry       Date:  2010-09-14       Impact factor: 15.992

6.  Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons.

Authors:  H M Critchlow; P R Maycox; J N Skepper; O Krylova
Journal:  Mol Cell Neurosci       Date:  2006-07-17       Impact factor: 4.314

Review 7.  Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders.

Authors:  Kevin C F Fone; M Veronica Porkess
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

8.  Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action.

Authors:  C Tomasetti; C Dell'Aversano; F Iasevoli; A de Bartolomeis
Journal:  Neuroscience       Date:  2007-08-28       Impact factor: 3.590

9.  A Disc1 mutation differentially affects neurites and spines in hippocampal and cortical neurons.

Authors:  A M Lepagnol-Bestel; M Kvajo; M Karayiorgou; M Simonneau; J A Gogos
Journal:  Mol Cell Neurosci       Date:  2013-02-06       Impact factor: 4.314

10.  PSD-95 promotes synaptogenesis and multiinnervated spine formation through nitric oxide signaling.

Authors:  Irina Nikonenko; Bernadett Boda; Sylvain Steen; Graham Knott; Egbert Welker; Dominique Muller
Journal:  J Cell Biol       Date:  2008-12-15       Impact factor: 10.539

View more
  40 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.

Authors:  Frederike Schirmbeck; Daniela Mier; Christine Esslinger; Franziska Rausch; Susanne Englisch; Sarah Eifler; Andreas Meyer-Lindenberg; Peter Kirsch; Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

3.  The promises and challenges of human brain organoids as models of neuropsychiatric disease.

Authors:  Giorgia Quadrato; Juliana Brown; Paola Arlotta
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

4.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

5.  Higher zinc concentrations in hair of Parkinson's disease are associated with psychotic complications and depression.

Authors:  Altair Brito Dos Santos; Marcos A Bezerra; Marcelo E Rocha; George E Barreto; Kristi A Kohlmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-07-11       Impact factor: 3.575

6.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

7.  Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.

Authors:  Jordyn M Kippe; Toni M Mueller; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2015-06-20       Impact factor: 4.939

Review 8.  Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons.

Authors:  Christa W Habela; Hongjun Song; Guo-Li Ming
Journal:  Mol Cell Neurosci       Date:  2015-12-02       Impact factor: 4.314

Review 9.  Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia.

Authors:  Dasiel O Borroto-Escuela; Julia Pintsuk; Thorsten Schäfer; Kristina Friedland; Luca Ferraro; Sergio Tanganelli; Fang Liu; Kjell Fuxe
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

10.  Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.

Authors:  Fernando J Bustos; Estibaliz Ampuero; Nur Jury; Rodrigo Aguilar; Fahimeh Falahi; Jorge Toledo; Juan Ahumada; Jaclyn Lata; Paula Cubillos; Berta Henríquez; Miguel V Guerra; Jimmy Stehberg; Rachael L Neve; Nibaldo C Inestrosa; Ursula Wyneken; Marco Fuenzalida; Steffen Härtel; Miguel Sena-Esteves; Lorena Varela-Nallar; Marianne G Rots; Martin Montecino; Brigitte van Zundert
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.